Story
Stock Market Highlights: Sensex ends 562 pts lower at 49,801, Nifty at 14,721; Reliance, SBI, ONGC top losers
Stock Market News Update Today: The BSE Sensex closed 562.34 points or 1.12 per cent lower at 49,801.62, and the NSE Nifty ended at 14,721.30, down by 189.15 points or 1.27 per cent
BusinessToday.In | March 17, 2021 | Updated 17:13 IST
Share Market Live News: Reliance Industries, State Bank of India, Asian Paints, Kotak Mahindra Bank, Bajaj Finance were top losers
Indian benchmark indices ended lower for the fourth consecutive session on Wednesday, weighed down by sharp losses in oil and gas and PSU stocks as well as weak global cues. The BSE Sensex closed 562.34 points or 1.12 per cent lower at 49,801.62, and the NSE Nifty ended at 14,721.30, down by 189.15 points or 1.27 per cent. The broader markets underperformed the BSE benchmark as midcap and smallcap indices declined 2.33 per cent and 2.16 per cent, respectively. Caution prevailed in the market ahead of US
NEW DELHI: Nifty Pharma index was trading with losses at 01:50PM (IST) on Wednesday. Shares of Lupin (down 2.42 per cent), Cipla (down 2.06 per cent), Sun Pharma (down 2.0 per cent), Dr Reddy s Laboratories (down 1.77 per cent) and Cadila Healthcare (down 1.6 per cent) were the top losers in the index. While Aurobindo Pharma (up 0.78 per cent) were among the top gainers. The Nifty Pharma index was trading 1.3 per cent down at 11856.4 around 01:50PM. Benchmark NSE Nifty50 index was down 88.60 points at 14821.85, while the BSE Sensex was down 228.83 points at 50135.13. Among the 50 stocks in the Nifty index, 7 were trading in the green, while 43 were in the red.
Search jobs 16-Mar-2021 Global Primary Pulmonary Hypertension (PPH) Treatment Market 2021:Size,Share,Trends,Analysis,Competitive Landscape Report To 2028||Players-GlaxoSmithKline PLC., Teva Pharmaceuticals Industries Ltd. (USA), Actelion Pharmaceuticals US, Inc
“Global Primary Pulmonary Hypertension (PPH) Treatment Market–Industry Trends and Forecast to 2028” New Research Report Added to Databridgemarketresearch.com database. The report width Of pages : 350 Figures: 60 And Tables: 220 in it.The global Primary Pulmonary Hypertension (PPH) Treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions and others to increase their footprints in this market. The report includes market shares of Primary Pulmonary Hypertension (PPH) Treatment market for global, Europe, North America, Asia Pacific and South Ameri
Story
Stock Market Highlights: Sensex ends 31 pts lower, Nifty at 14,910; ICICI Bank, SBI, HDFC Bank top losers
Stock Market News Update Today: ICICI Bank, State Bank of India, Kotak Mahindra Bank, HDFC Bank, NTPC were notable losers on the BSE Sensex pack
BusinessToday.In | March 16, 2021 | Updated 16:30 IST
Share Market News: Sensex, Nifty end marginally lower
Paring early morning gains, the Indian benchmark indices ended marginally lower on Monday, weighed down by losses in metal and bank stocks. The BSE Sensex ended at 50,363, down 31 points or by 0.06 per cent, and the NSE Nifty ended 19 points or 0.3 per cent lower at 14,910. Bucking the trend, the broader markets ended higher, with MidCap and SmallCap indices rising 0.4 per cent and 0.32 per cent, respectively. The BSE Sensex touched intraday high of 50,857.98 and intraday low of 50,289.44, while the NSE Nifty touched intraday high of 15,051.6 and intraday low of 14,890.65. Among the individual stocks Asian Paints, Dr. R
Share:
The generic oncology drugs market is expected to reach US$ 36,029.60 Mn in 2027 from US$ 21,200.00 in 2018. The market is estimated to grow with a CAGR of 6.3% from 2019-2027.
The key factors such as increasing prevalence of cancer across the globe, growing generic drug launches and benefits offered by the generic drugs are likely to boost the market growth, whereas, inclination towards the personalized medicine for cancer is likely to be a prevalent trend in the future years. Asia Pacific generic oncology drugs market is expected to grow at highest rate during the forecast period. The growth is contributed by the key driving factors such as development of generics at mass scale, increasing exports by Indian manufacturers, new trade agreements by Asian companies with international players for sales, distribution as well as research collaborations as well as launch of innovative and novel generics for cancer treatment. The market for generic oncology drugs in the Asia Pacif